Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03

被引:86
作者
MacManus, Michael [1 ,2 ]
Fisher, Richard [1 ]
Roos, Daniel [4 ,5 ]
O'Brien, Peter [6 ]
Macann, Andrew [10 ]
Davis, Sidney [3 ]
Tsang, Richard [11 ]
Christie, David [8 ]
McClure, Bev [1 ]
Joseph, David [9 ]
Jayamohan, Jayasingham [7 ]
Seymour, John F. [1 ,2 ]
机构
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Alfred Hosp, Prahran, Vic, Australia
[4] Royal Adelaide Hosp, Adelaide, SA, Australia
[5] Univ Adelaide, Adelaide, SA, Australia
[6] Genesis Canc Care, Newcastle, NSW, Australia
[7] Westmead Hosp, Sydney, NSW, Australia
[8] Genesis Canc Care, Tugun, Qld, Australia
[9] Sir Charles Gairdner Hosp Perth, Perth, WA, Australia
[10] Auckland City Hosp, Auckland, New Zealand
[11] Princess Margaret Hosp, Toronto, ON, Canada
关键词
COMBINED-MODALITY THERAPY; NON-HODGKIN-LYMPHOMA; TERM-FOLLOW-UP; LOW-GRADE; RADIATION-THERAPY; 1ST-LINE TREATMENT; DOSE RADIOTHERAPY; TOXICITY CRITERIA; PLUS RITUXIMAB; PHASE-III;
D O I
10.1200/JCO.2018.77.9892
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeFollicular lymphoma (FL) is curable by involved-field radiotherapy (IFRT) in < 50% of patients with stage I to II disease. We hypothesized that adding systemic therapy to IFRT would improve long-term progression-free survival (PFS).Patients and MethodsA multicenter randomized controlled trial enrolled patients with stage I to II low-grade FL after staging computed tomography scans and bone marrow biopsies. F-18-labeled fluorodeoxyglucose-positron emission tomography (PET) was not mandatory. Patients were randomly assigned to either arm A (30 Gy IFRT alone) or arm B (IFRT plus six cycles of cyclophosphamide, vincristine, and prednisolone [CVP]). From 2006, rituximab was added to arm B (R-CVP).ResultsBetween 2000 and 2012, 150 patients were enrolled, 75 per arm. In arm B, 44 patients were allocated to receive CVP and 31 were allocated to receive R-CVP. At randomization, 75% had stage I, the median age was 57 years, 52% were male, and 48% were PET staged. With a median follow-up of 9.6 years (range, 3.1 to 15.8 years), PFS was superior in arm B (hazard ratio, 0.57; 95% CI, 0.34 to 0.95; P = .033). Ten-year PFS rates were 59% (95% CI, 46% to 74%) and 41% (95% CI, 30% to 57%) for arms B and A, respectively. Patients in arm B who received R-CVP had markedly superior PFS compared with contemporaneous patients in arm A (hazard ratio, 0.26; 95% CI, 0.07 to 0.97; P = .045). Fewer involved regions (P = .047) and PET staging (P = .056) were associated with better PFS. Histologic transformation occurred in four and 10 patients in arms B and A, respectively (P = .1). Ten deaths occurred in arm A versus five in arm B, but overall survival was not significantly different (P = .40; 87% and 95% at 10 years, respectively).ConclusionSystemic therapy with R-CVP after IFRT reduced relapse outside radiation fields and significantly improved PFS. IFRT followed by immunochemotherapy is more effective than IFRT in early-stage FL.
引用
收藏
页码:2918 / +
页数:10
相关论文
共 31 条
[1]   Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy [J].
Bains, P. ;
Al Tourah, A. ;
Campbell, B. A. ;
Pickles, T. ;
Gascoyne, R. D. ;
Connors, J. M. ;
Savage, K. J. .
ANNALS OF ONCOLOGY, 2013, 24 (02) :428-441
[2]  
BUSH RS, 1977, CANCER TREAT REP, V61, P1129
[3]   Long-Term Outcomes for Patients With Limited Stage Follicular Lymphoma Involved Regional Radiotherapy Versus Involved Node Radiotherapy [J].
Campbell, Belinda A. ;
Voss, Nick ;
Woods, Ryan ;
Gascoyne, Randy D. ;
Morris, James ;
Pickles, Tom ;
Connors, Joseph M. ;
Savage, Kerry J. .
CANCER, 2010, 116 (16) :3797-3806
[4]   TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[5]   Follicular lymphoma: time for a re-think? [J].
Gandhi, MK ;
Marcus, RE .
BLOOD REVIEWS, 2005, 19 (03) :165-178
[6]   PROGNOSTIC FACTORS IN NODULAR LYMPHOMAS - A MULTIVARIATE-ANALYSIS BASED ON THE PRINCESS-MARGARET-HOSPITAL EXPERIENCE [J].
GOSPODAROWICZ, MK ;
BUSH, RS ;
BROWN, TC ;
CHUA, T .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (04) :489-497
[7]   Low dose radiotherapy in indolent lymphomas, enough is enough [J].
Haas, R. L. M. .
HEMATOLOGICAL ONCOLOGY, 2009, 27 (02) :71-81
[8]   4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non- inferiority trial [J].
Hoskin, Peter J. ;
Kirkwood, Amy A. ;
Popova, Bilyana ;
Smith, Paul ;
Robinson, Martin ;
Gallop-Evans, Eve ;
Coltart, Stewart ;
Illidge, Timothy ;
Madhavan, Krishnaswamy ;
Brammer, Caroline ;
Diez, Patricia ;
Jack, Andrew ;
Syndikus, Isabel .
LANCET ONCOLOGY, 2014, 15 (04) :457-463
[9]  
Kelsey CR, 2012, ONCOLOGY-NY, V26, P1182
[10]   A BRITISH-NATIONAL-LYMPHOMA-INVESTIGATION RANDOMIZED TRIAL OF SINGLE-AGENT CHLORAMBUCIL PLUS RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN LOW-GRADE, LOCALIZED NON-HODGKINS-LYMPHOMA [J].
KELSEY, SM ;
NEWLAND, AC ;
HUDSON, GV ;
JELLIFFE, AM .
MEDICAL ONCOLOGY, 1994, 11 (01) :19-25